Physician profile
Ryan D Melvin
NPI 1679919724
$10,044.28
in general payments reported to CMS, 2019-2025
18 companies · $311 in 2025
The $311 reported for 2025 was less than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $7,666 · 2020: $487 · 2021: $156 · 2022: $177 · 2024: $1,247 · 2025: $311.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Travel and Lodging: $987 · Food and Beverage: $571.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Travel and Lodging | $987.35 |
| Food and Beverage | $570.90 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Csl Behring | $6,353.75 | 2019 | |
| Abbott Laboratories | $2,351.81 | 2019-2024 | Mitraclip |
| Boston Scientific Corporation | $246.57 | 2019-2021 | |
| Novartis Pharmaceuticals Corporation | $204.42 | 2019-2025 | |
| Astrazeneca Pharmaceuticals LP | $166.12 | 2019-2025 | Farxiga |
| Cardiovascular Systems INC. | $120.33 | 2019 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $112.72 | 2019-2025 | Lifevest |
| Actelion Pharmaceuticals US, INC. | $101.74 | 2020-2022 | |
| Amgen INC. | $87.47 | 2019-2025 | Repatha |
| Philips North America LLC | $55.33 | 2020-2025 | Affiniti Cvx |
| Merck Sharp & Dohme LLC | $51.04 | 2025 | Verquvo |
| E.R. Squibb & Sons, L.L.C. | $46.52 | 2019-2020 | |
| Janssen Pharmaceuticals, INC | $44.60 | 2019-2022 | |
| Cagent Vascular INC | $27.25 | 2025 | Serrantor |
| Medtronic Vascular, INC. | $24.38 | 2019 |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Daiichi Sankyo INC. | $19.88 | 2020 | |
| Inspire Medical Systems, INC. | $17.49 | 2025 | Inspire |
| Sanofi-Aventis U.S. LLC | $12.86 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ryan Melvin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.